Mountain Valley MD

Helping People Live Their Best Life

We provide our global nutraceutical, vaccine and pharmaceutical partners with unprecedented product and market advantages.

Mountain Valley MD

Our Quicksome™ desiccation delivery technology utilizes advanced liposomes and other stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats that are consumed orally.  The result is a new generation of product formulations that are capable of delivering vaccines, drugs and nutraceuticals into the body faster, with greater impact, efficiency and accuracy, providing our partners with unprecedented market advantages while dealing with some of the most significant challenges facing their companies:

  • Loss of Patent Exclusivity

  • Extending Profitability Against Generic Drug Competitors

  • Driving Down Drug and Vaccine Costs While Increasing Profitability

  • Enabling Broader Distribution of Drugs and Vaccines

  • Eliminating Significant Costs and Wastage Associated with Cold Chain Storage Requirements

  • Expanding Production Capacity for Global Blockbuster Drugs

ORAL Delivery technology

Mountain Valley MD is engaged in implementing its patented Quicksome™ oral delivery technologies across a variety of molecules in nutraceutical, vaccine and pharmaceutical drug applications. The Company’s patented Quicksome™ desiccation technology utilizes proprietary multi-stage liposomal formulation and manufacturing methods to encapsulate and formulate active ingredients into highly efficient first-in-class product formats that are dissolved orally under the tongue, without the use of needles.

Next Generation


Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and patented desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective product formats. The patented technology revolutionizes drug and nutraceutical ingredient delivery for superior health outcomes by simultaneously addressing a multitude of key drug and nutraceutical product efficacy challenges, such as low bioavailability, high absorption variability and poor dosage control.

  • Rapid Onset

  • High Bioavailability

  • Ease of Delivery

  • Precision Dosing Technology and Stability

Current News

“A needle-free, cost-effective, polio vaccine could be a major step towards global polio eradication. Mountain Valley MD’s Quicksome™ technology has already proven its ability to stabilize and preserve the Inactivated Poliovirus Vaccine (IPV) and I believe that this technology holds great promise in finally delivering a needle-free effective sublingual polio vaccine and probably many other globally needed vaccines as well.”

- Dr. John Clements,
  Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine

“The FDA’s Polio D Antigen preservation results demonstrate that Mountain Valley MD’s proprietary and patented Quicksome™ low temperature strip manufacturing technology can be successfully applied to heat labile vaccines, complex proteins such as insulin or glucagon, peptides and other molecules and constructs that are sensitive to heat and oxidation.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“With encouraging FDA Polio Lab validation, Mountain Valley MD is continuing work on development of our proprietary vaccine adjuvants for Polio and the necessary pre-clinical trials to demonstrate the unprecedented impact of our Quicksome™ technology.”

- Dennis Hancock, President and CEO of Mountain Valley MD

“For decades scientists have been working to solve the problem of vaccine instability and cold chain distribution with little progress. Approaches such as micro-needle applications, lyophilization, spray drying, and others have not reached commercialization due to problems of complexity, cost, and long-term stability challenges.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“We believe Mountain Valley MD’s patented Quicksome™ technology revolutionizes drug and nutraceutical ingredient delivery for superior health outcomes by simultaneously addressing a multitude of key drug and nutraceutical product efficacy challenges, such as low bioavailability, high absorption variability and poor dosage control.”

- Dennis Hancock, President and CEO of Mountain Valley MD

“Many of the active ingredients contained in traditional pharmaceutical drugs and nutraceutical supplements are not well absorbed and suffer extensive degradation during first pass metabolism.  We feel this is exactly the problem that Mountain Valley MD’s direct-to-mouth Quicksome™ technology solves, dramatically improving bioavailability of compounds that are traditionally heavily metabolized by MAO enzymes, glucuronidation and other conjugation processes”.

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“We have an amazingly talented team that is working on solving some very advanced challenges in the health and wellness space.  To date we have done research and development work with more than 60 molecules for a variety of nutraceutical and pharmaceutical applications, including drugs, vaccines, the emerging mushroom space and cannabinoids.”

- Dennis Hancock, President and CEO of Mountain Valley MD

“For me personally, the idea that our delivery technology could help dispense drugs such as insulin or deliver vaccines into the body through a rapid dissolve sublingual strip and eliminate the need for painful needle injections is truly game changing.”

- Dennis Hancock, President and CEO of Mountain Valley MD

Subscribe for Updates

Stay plugged in on everything Mountain Valley MD.

THANK YOU FOR YOUR INTEREST IN OUR STORY.
Please check your inbox to confirm your subscription.
Oops! Something went wrong while submitting the form.
*By Clicking "Sign Up" You agree to Mountain Valley MD's Privacy Policy
Subscribe